UK-based charity commission Brain Tumour Charity has announced that the STELLAR trial, which will test the safety and efficacy of eflornithine, is now open for patients to enrol.
Eflornithine is an oral regimen used to treat patients identified with recurring anaplastic astrocytoma.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The STELLAR trial is a Phase III clinical trial that aims to study oral eflornithine as a possible novel treatment for recurrent anaplastic astrocytoma.
Funded by Orbus Therapeutices, the trial is now open to eligible patients for enrolment across North America, Europe and selected sites in the UK.
The Brain Tumour Charity commission said in a statement: “Anaplastic astrocytoma brain tumours are most common in adults aged 30 to 50 years, although it can affect all ages if they recur after surgery, chemotherapy or radiotherapy there are currently few treatments available, something the STELLAR trial aims to investigate.”
This Phase III clinical trial is designed to show if eflornithine can inhibit malignant tumour growth, including intracerebral high-grade gliomas.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUnder this trial, eflornithine will be administered orally and will target a key enzyme called ornithine decarboxylase. This enzyme plays a major role in the growth of cancer cells in the brain.
In 2014, eflornithine received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic glioma.
